Identification of Asthma Phenotypes in Severe Asthmatics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01623089|
Recruitment Status : Recruiting
First Posted : June 19, 2012
Last Update Posted : July 28, 2021
Asthma is a heterogenous disease. Different patients have different presentations, course of disease and response to treatment.
The investigators would like to study our population of more severe asthma and find out about their profile - demographic, clinical and inflammatory.
|Condition or disease|
Asthma is a heterogeneous disorder presenting with many phenotypes. Most asthmatics have mild to moderate disease. However, 5-20% of asthmatics belong to the "Difficult-to-treat" or more severe group and they account for 50-80% of asthma health care costs. In a tertiary hospital like Singapore General Hospital, most of our asthmatics belong to the more severe group. They have more frequent healthcare visits, hospitalizations, medication use and higher risks of death.
There is currently no local data on the phenotypic profile of our patients. Asthma phenotypes which have been identified include those related to triggers ( eg. drugs such as aspirin or NSAIDS, environmental allergen, occupational allergens or irritants, exercise) or clinical physiological phenotypes ( eg. severity-defined, exacerbation-prone, chronic airflow limitation, steroid-resistant, age -of -onset) or inflammatory phenotypes ( eg. eosinophilic, neutrophilic, pauci granulocytic, mixed). With better understanding of their phenotypes, treatment can then be individually tailored to improve their asthma control and reduce future risks.
We aim to improve the understanding of this group of asthmatics such that better treatment approaches can be developed in the future. This is not a clinical trial. Its purpose is to gather information ranging from demographic data, medical history to responses to simple routine questions, to lung function, inflammation, allergy and blood testing results. The data are analyzed to improve our understanding of the clinical and inflammatory phenotypes ( or profiles) in this group of patients.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Identification of Asthma Phenotypes in Severe Asthmatics|
|Actual Study Start Date :||January 2, 2011|
|Estimated Primary Completion Date :||January 2025|
|Estimated Study Completion Date :||January 2026|
- Annual exacerbation rates [ Time Frame: Through study completion, an average of 1 year ]Annual exacerbation rates
- Symptom control [ Time Frame: Through study completion, an average of 1 year ]Symptom control using Asthma Control Test
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623089
|Singapore General Hospital||Recruiting|
|Singapore, Singapore, 169608|
|Contact: Mariko Koh, MBBS (65) 64699419 firstname.lastname@example.org|
|Principal Investigator:||Mariko Koh, MBBS||Singapore General Hospital|